DANCAN Stock Overview
Dancann Pharma A/S, a biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing cannabinoid therapeutics in various disease areas.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Dancann Pharma A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr.0.056 |
| 52 Week High | kr.0.58 |
| 52 Week Low | kr.0.01 |
| Beta | 2.21 |
| 1 Month Change | -26.51% |
| 3 Month Change | 194.74% |
| 1 Year Change | -89.86% |
| 3 Year Change | -98.74% |
| 5 Year Change | n/a |
| Change since IPO | -98.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| DANCAN | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 86.7% | 1.0% | 1.4% |
| 1Y | -89.9% | 54.0% | 8.6% |
Return vs Industry: DANCAN underperformed the Swedish Pharmaceuticals industry which returned 55.7% over the past year.
Return vs Market: DANCAN underperformed the Swedish Market which returned 4.4% over the past year.
Price Volatility
| DANCAN volatility | |
|---|---|
| DANCAN Average Weekly Movement | 40.2% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.3% |
| 10% least volatile stocks in SE Market | 3.6% |
Stable Share Price: DANCAN's share price has been volatile over the past 3 months.
Volatility Over Time: DANCAN's weekly volatility has increased from 28% to 40% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 10 | Jeppe Rasmussen | www.dancann.com |
Dancann Pharma A/S, a biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing cannabinoid therapeutics in various disease areas. The company produces and distributes prescription and over-the-counter cannabinoid-based pharmaceuticals primarily focused on pain patients. Dancann Pharma A/S was incorporated in 2018 and is based in Ansager, Denmark.
Dancann Pharma A/S Fundamentals Summary
| DANCAN fundamental statistics | |
|---|---|
| Market cap | kr.9.33m |
| Earnings (TTM) | -kr.12.34m |
| Revenue (TTM) | kr.7.15m |
1.3x
P/S Ratio-0.8x
P/E RatioIs DANCAN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DANCAN income statement (TTM) | |
|---|---|
| Revenue | kr.7.15m |
| Cost of Revenue | kr.10.61m |
| Gross Profit | -kr.3.46m |
| Other Expenses | kr.8.88m |
| Earnings | -kr.12.34m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.074 |
| Gross Margin | -48.32% |
| Net Profit Margin | -172.53% |
| Debt/Equity Ratio | 0% |
How did DANCAN perform over the long term?
See historical performance and comparison